{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-137228","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.068360+00:00","generated_at":"2026-06-02T01:50:06.548182+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Inovio Q1 net loss narrows to $30.5M; BLA for INO-3107 on track for H2 2024","bullets":["BLA submission for INO-3107 (recurrent respiratory papillomatosis) on track for H2 2024 under accelerated approval pathway.","Phase 3 trial of INO-3112 + LOQTORZI for HPV-related throat cancer advancing; FDA feedback received.","Net loss $30.5M ($1.31/sh) vs $40.6M ($1.89/sh) in Q1 2023; R&D expenses fell to $20.9M.","Cash & equivalents $105.6M at Mar 31, 2024; April offering raised net ~$33.2M; cash runway into Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-137228","json":"https://secwatch.observer/filing/0001193125-24-137228.json","markdown":"https://secwatch.observer/filing/0001193125-24-137228.md","text":"https://secwatch.observer/filing/0001193125-24-137228.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000119312524137228/0001193125-24-137228-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000119312524137228/d774987d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:50:06.548182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8bae482f20dea374448199aab8b94c79ed3b2604","claim":"INOVIO PHARMACEUTICALS, INC. reported financial results for first quarter of 2024.","evidence_excerpt":"On May 13, 2024, Inovio Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1055726/000119312524137228/0001193125-24-137228-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}